FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:99-110 January 12, 1995 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Benign prostatic hyperplasia is a nonmalignant enlargement of the prostate that is due to excessive cellular growth of both the glandular and the stromal elements of the gland. The condition is very common in men over 40 years of age of all races and cultures.^{1,2,3,4,5,6,7,8} For the past 50 years, transurethral resection of the prostate has been the mainstay of treatment. Approximately 400,000 such resections are performed annually in the United States, making this operation the second most common after cataract extraction in men older than 65.⁹ The associated expense is considerable; the total cost is approximately $5 billion per . . . [Full Text of this Article]

Evaluating Treatment Options

Medical Treatments

Androgen-Deprivation Therapy

Drugs That Inhibit 5-Reductase Activity

-Adrenergic–Antagonist Drugs

Summary of Medical Therapies

Minimally Invasive Treatments

Transurethral Incision of the Prostate

Prostatic Stents

Microwave Therapy

Laser Prostatectomy

Summary of Minimally Invasive Treatments

Deciding on the Right Treatment for Each Patient

Source Information

From the Michigan Prostate Center, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, where reprint requests should be addressed to Dr. Oesterling.

References

Related Letters:

Treatment of Benign Prostatic Hyperplasia
Eisenberg L., Wasson J. H., Reda D. J., Bruskewitz R. C., Oesterling J. E.
Extract | Full Text  
N Engl J Med 1995; 332:1716-1717, Jun 22, 1995. Correspondence

This article has been cited by other articles:

• Ouslander, J. G. (2004). Management of Overactive Bladder. NEJM 350: 786-799 [Full Text]  
• Wilt, T. J (2002). Treatment options for benign prostatic hyperplasia. BMJ 324: 1047-1048 [Full Text]  
• Brookes, S. T, Donovan, J. L, Peters, T. J, Abrams, P., Neal, D. E (2002). Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 324: 1059-1059 [Abstract] [Full Text]  
• Hudson, D. L., Guy, A. T., Fry, P., O'Hare, M. J., Watt, F. M., Masters, J. R.W. (2001). Epithelial Cell Differentiation Pathways in the Human Prostate: Identification of Intermediate Phenotypes by Keratin Expression. J. Histochem. Cytochem. 49: 271-278 [Abstract] [Full Text]  
• Lenert, L. A., Cher, D. J. (1999). Use of Meta-analytic Results to Facilitate Shared Decision Making. J. Am. Med. Inform. Assoc. 6: 412-419 [Abstract] [Full Text]  
• Wilt, T. J., Ishani, A., Stark, G., MacDonald, R., Lau, J., Mulrow, C. (1998). Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia: A Systematic Review. JAMA 280: 1604-1609 [Abstract] [Full Text]  
• McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M., Waldstreicher, J., The Finasteride Long-Term Efficacy and Safety Stud, (1998). The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia. NEJM 338: 557-563 [Abstract] [Full Text]  
• Wasson, J. H. (1998). Finasteride to Prevent Morbidity from Benign Prostatic Hyperplasia. NEJM 338: 612-613 [Full Text]  
• Taguchi, K., Saitoh, M., Sato, S., Asano, M., Michel, M. C. (1997). Effects of Tamsulosin Metabolites at Alpha-1 Adrenoceptor Subtypes. J. Pharmacol. Exp. Ther. 280: 1-5 [Abstract] [Full Text]  
• Walsh, P. C. (1996). Treatment of Benign Prostatic Hyperplasia. NEJM 335: 586-587 [Full Text]  
• Eisenberg, L., Wasson, J. H., Reda, D. J., Bruskewitz, R. C., Oesterling, J. E. (1995). Treatment of Benign Prostatic Hyperplasia. NEJM 332: 1716-1717 [Full Text]  
• (1995). Finasteride and benign prostatic hyperplasia. DTB 33: 19-21 [Abstract] [Full Text]  
• (1995). Surgery vs. Watchful Waiting for BPH. Journal Watch Dermatology 1995: 18-18 [Full Text]  
• (1995). SURGERY VS. WATCHFUL WAITING FOR BPH. JWatch General 1995: 2-2 [Full Text]